Journal Article

Treating dyslipidaemia in the patient with type 2 diabetes

D.J. Betteridge

in European Heart Journal Supplements

Published on behalf of European Society of Cardiology

Volume 6, issue suppl_C, pages C28-C33
Published in print July 2004 | ISSN: 1520-765X
Published online July 2004 | e-ISSN: 1554-2815 | DOI:
Treating dyslipidaemia in the patient with type 2 diabetes

Show Summary Details


Cardiovascular disease (CVD) is a major cause of morbidity and mortality in patients with type 2 diabetes. Individuals with diabetes are at a much greater risk of developing CVD than those without diabetes, and have a much poorer outcome. For any given concentration of plasma cholesterol, the risk of CVD is approximately three times higher in subjects with diabetes, compared with those without the disease. The mechanisms underlying this increase in risk not only involve hyperglycaemia but also other major risk factors, such as dyslipidaemia and hypertension, which are potentially modifiable. The involvement of multiple risk factors in diabetes underlines the fact that it is a vascular disease, requiring total risk factor management. Diabetic dyslipidaemia is characterized by hypertriglyceridaemia, the accumulation of cholesterol-rich remnant particles, small dense low-density lipoprotein (LDL) and low high-density lipoprotein (HDL). Clinical trials have provided unequivocal evidence of the importance of lipid-lowering therapy in the secondary prevention of CVD in patients with diabetes. Lipid-lowering therapy is also beneficial in the primary prevention setting. Further information will become available from ongoing prospective studies in specific lower-risk diabetic populations.

Keywords: Diabetic dyslipidaemia; Hypertriglyceridaemia; Lipid-lowering therapy; Low-density lipoprotein; Type 2 diabetes

Journal Article.  4271 words.  Illustrated.

Subjects: Cardiovascular Medicine

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.